Glipizide sustained release tablets

Abstract

The invention relates to glipizide sustained release tablets for treating diabetes mellitus. The technical scheme provided by the invention is as follows: the glipizide sustained release tablets are characterized in that every 1,000 glipizide sustained release tablets contain 5g of glipizide, 26g of hydroxypropyl methylcellulose (K15M) and 6.5g of sodium carboxymethylcellulose.

Description

[0001] Technical Field The present invention relates to a glipizide sustained-release tablet for treating diabetes. Background technique [0002] Diabetes is an epidemic in the 21st century, and it is the third largest disease after cardiovascular disease and cancer. In my country, with the improvement of people's material life and medical diagnosis level, the number of diabetic patients has increased year by year, and it has reached about 30 million at present. About 95% of them belong to type 2 diabetes. Sulfonylureas (SU) are oral hypoglycemic drugs with the earliest application, the largest variety, and the most extensive clinical application. Among them, glipizide has the fastest development speed. Since the second half of 2003, the product’s The sales surpassed the once famous gliclazide, becoming the sulfonylurea hypoglycemic drug with the highest sales. Glipizide preparations that have been marketed include regular tablets and sustained-release tablets. [0003] Gli...

AI Technical Summary

Problems solved by technology

During the preparation process of Glipizide Sustained-release Tablets, if the formulation design is improper, there will be problems that the release rate is difficult to reach the standard. At the same time, there will be problems such as high viscosity of the mixture and high particle hardness during the granulation process.

Images